A recent meta-analysis conducted by Xu et al. demonstrated that the use of SGLT2 inhibitors was associated with improved oncological outcomes, including a significant reduction in cancer-related mortality and disease progression [77]. The gene discussed is SLC5A2; the disease is cancer.